Hemolytic uremic syndrome following autologous peripheral blood stem cell transplantation in a patient with malignant lymphoma.

Abstract

Hemolytic uremic syndrome (HUS) has been reported in patients receiving bone marrow transplantation. However, only a few cases of HUS following autologous peripheral blood stem cell transplantation (PBSCT) have been reported. We present a case of HUS developing after autologous PBSCT in a 40-year-old man with non-Hodgkin's lymphoma. It appears that the chemotherapeutic agents administered during the conditioning regimen for PBSCT may have played an important role in the development of HUS in our patient. In the present case, the combination therapy of vincristine, methylprednisolone, and ticlopidine hydrochloride was effective.

• Authors: E Ohno, E Ohtsuka, T Iwashita, N Uno, M Ogata, H Kikuchi, M Nasu
• Journal: Bone marrow transplantation (Bone Marrow Transplant) Vol. 19 Issue 10 Pg. 1045-7 (May 1997) ISSN: 0268-3369 [Print] England
• PMID: 9169652 (Publication Type: Case Reports, Journal Article)

Chemical References

• Vincristine

Topics

• Adult
• Antineoplastic Combined Chemotherapy Protocols (adverse effects)
• Hematopoietic Stem Cell Transplantation (adverse effects)
• Hemolytic-Uremic Syndrome (etiology)
• Humans
• Lymphoma, Large B-Cell, Diffuse (therapy)
• Male
• Transplantation Conditioning (adverse effects)
• Transplantation, Autologous
• Vincristine (adverse effects)